| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0528 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0528 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0528 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0778 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0944 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0954 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.0990 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1220 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1233 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1259 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1298 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1476 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1706 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1752 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1783 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1814 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1889 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1957 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.1960 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.2125 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.2245 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.2394 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.2613 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.2620 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.2642 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3032 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3214 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3230 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3354 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3413 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3506 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3515 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3529 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3562 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3604 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3659 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3774 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.3927 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4055 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4072 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4100 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4153 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4331 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4355 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4381 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4384 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4418 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4460 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4509 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4542 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4549 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4579 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4649 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4710 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4761 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4804 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4936 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4949 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.4982 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.5040 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.5064 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.5536 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.5829 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.5845 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6057 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6074 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6098 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6145 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6192 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6199 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6214 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6414 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6452 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6612 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6691 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6719 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.6918 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.7271 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.7361 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.7374 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.7640 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.7899 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8200 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8408 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8441 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8621 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8859 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8934 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.8942 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.9534 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.9769 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 0.9871 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0129 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0231 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0538 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0624 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0798 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0842 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0851 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.0974 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.1509 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.1811 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2154 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2384 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2480 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2688 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2781 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2827 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.2884 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.3249 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.3623 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.3858 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.4016 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.4149 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.4549 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.4550 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.4843 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.5602 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.6019 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.6020 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.6742 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.6822 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.6860 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.7030 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.7948 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.8873 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.8948 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.9014 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 1.9944 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.0455 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.0597 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.0985 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.1093 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.1216 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.1226 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.2852 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.3711 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.3775 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.4687 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.4727 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.4958 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.4983 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.5757 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.6266 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.6468 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.7205 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.7259 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.7397 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 2.9906 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.0572 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.1249 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.1455 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.3163 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.4753 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.5208 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.5990 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.7051 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 3.9005 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.0656 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.3333 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.3408 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.4308 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.4820 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.7606 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.7635 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.7863 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 4.8444 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 5.0369 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 5.1550 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 5.4393 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 5.7115 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 5.9884 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 6.5273 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 7.3173 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 7.3886 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 8.6359 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 10.7065 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 12.5359 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 13.5048 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 15.6313 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 17.6857 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycoursodeoxycholate | 19.7621 | scaled units | Low-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|